메뉴 건너뛰기




Volumn 33, Issue 3, 2015, Pages 720-728

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

Author keywords

Colorectal carcinoma; MK 2206; pAKT; pERK; Selumetinib

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; FUSED HETEROCYCLIC RINGS; SELUMETINIB; TUMOR MARKER;

EID: 84939934190     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0212-z     Document Type: Article
Times cited : (103)

References (17)
  • 1
    • 79952392909 scopus 로고    scopus 로고
    • Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
    • 10.1002/gcc.20854 1:CAS:528:DC%2BC3MXivVGjs74%3D 21305640
    • Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS (2011) Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50(5):307-312. doi: 10.1002/gcc.20854
    • (2011) Genes Chromosomes Cancer , vol.50 , Issue.5 , pp. 307-312
    • Vaughn, C.P.1    Zobell, S.D.2    Furtado, L.V.3    Baker, C.L.4    Samowitz, W.S.5
  • 3
    • 0036195196 scopus 로고    scopus 로고
    • AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis
    • 1:CAS:528:DC%2BD38XptFSqtA%3D%3D 11756242
    • Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23(1):201-205
    • (2002) Carcinogenesis , vol.23 , Issue.1 , pp. 201-205
    • Roy, H.K.1    Olusola, B.F.2    Clemens, D.L.3    Karolski, W.J.4    Ratashak, A.5    Lynch, H.T.6    Smyrk, T.C.7
  • 4
    • 84863596086 scopus 로고    scopus 로고
    • MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
    • 10.1158/0008-5472.CAN-11-3747 3515079 1:CAS:528:DC%2BC38XpsFKktbk%3D 22552284
    • Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72(13):3228-3237. doi: 10.1158/0008-5472.CAN-11-3747
    • (2012) Cancer Res , vol.72 , Issue.13 , pp. 3228-3237
    • Turke, A.B.1    Song, Y.2    Costa, C.3    Cook, R.4    Arteaga, C.L.5    Asara, J.M.6    Engelman, J.A.7
  • 5
    • 77956280407 scopus 로고    scopus 로고
    • PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling
    • 10.1158/0008-5472.CAN-10-0409 3178450 1:CAS:528:DC%2BC3cXhtV2rsLbJ 20699365
    • Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70(17):6804-6814. doi: 10.1158/0008-5472.CAN-10-0409
    • (2010) Cancer Res , vol.70 , Issue.17 , pp. 6804-6814
    • Halilovic, E.1    She, Q.B.2    Ye, Q.3    Pagliarini, R.4    Sellers, W.R.5    Solit, D.B.6    Rosen, N.7
  • 8
    • 34548097240 scopus 로고    scopus 로고
    • AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
    • 10.1158/1535-7163.MCT-07-0231 1:CAS:528:DC%2BD2sXptVGltb8%3D 17699718
    • Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, Cockerill M, Cartlidge S, Smith PD (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6(8):2209-2219. doi: 10.1158/1535-7163.MCT-07-0231
    • (2007) Mol Cancer Ther , vol.6 , Issue.8 , pp. 2209-2219
    • Davies, B.R.1    Logie, A.2    McKay, J.S.3    Martin, P.4    Steele, S.5    Jenkins, R.6    Cockerill, M.7    Cartlidge, S.8    Smith, P.D.9
  • 10
    • 77954615408 scopus 로고    scopus 로고
    • MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo
    • 10.1158/1535-7163.MCT-09-1012 1:CAS:528:DC%2BC3cXhtFertbnL 20571069
    • Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, Kotani H (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956-1967. doi: 10.1158/1535-7163.MCT-09-1012
    • (2010) Mol Cancer Ther , vol.9 , Issue.7 , pp. 1956-1967
    • Hirai, H.1    Sootome, H.2    Nakatsuru, Y.3    Miyama, K.4    Taguchi, S.5    Tsujioka, K.6    Ueno, Y.7    Hatch, H.8    Majumder, P.K.9    Pan, B.S.10    Kotani, H.11
  • 16
    • 80051899599 scopus 로고    scopus 로고
    • Differential gene expression signatures between colorectal cancers with and without KRAS mutations: Crosstalk between the KRAS pathway and other signalling pathways
    • 10.1016/j.ejca.2011.03.029 1:CAS:528:DC%2BC3MXhtVGmtr7I 21531130
    • Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H, Eshima K (2011) Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 47(13):1946-1954. doi: 10.1016/j.ejca.2011.03.029
    • (2011) Eur J Cancer , vol.47 , Issue.13 , pp. 1946-1954
    • Watanabe, T.1    Kobunai, T.2    Yamamoto, Y.3    Matsuda, K.4    Ishihara, S.5    Nozawa, K.6    Iinuma, H.7    Ikeuchi, H.8    Eshima, K.9
  • 17
    • 84870184240 scopus 로고    scopus 로고
    • Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials
    • 3531821 1:CAS:528:DC%2BC38Xhs12hu7nE 22974395
    • Ang JE, Kaye S, Banerji U (2012) Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials. Curr Drug Targets 13(12):1525-1534
    • (2012) Curr Drug Targets , vol.13 , Issue.12 , pp. 1525-1534
    • Ang, J.E.1    Kaye, S.2    Banerji, U.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.